Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, founded in 2002. The company pioneered RNA interference (RNAi) therapeutics, a novel class of medicines that silence disease-causing genes at the molecular level.
Alnylam focuses on discovering, developing, and commercializing RNAi-based drugs for genetically defined diseases, including rare and prevalent conditions in areas such as amyloidosis, porphyria, hyperoxaluria, and cardiovascular disorders. Its approved products include ONPATTRO (patisiran) for hATTR amyloidosis polyneuropathy, GIVLAARI (givosiran) for acute hepatic porphyria, OXLUMO (lumasiran) for primary hyperoxaluria type 1, AMVUTTRA (vutrisiran) for ATTR amyloidosis, and others like Leqvio (inclisiran, licensed to Novartis).
With a robust pipeline of investigational RNAi therapeutics and subsidiaries in Europe, North America, and Asia-Pacific, Alnylam (NASDAQ: ALNY) continues to advance gene-silencing technologies. Note: While RNAi involves nucleic acid chemistry, Alnylam operates primarily in biopharmaceuticals, not traditional chemical manufacturing.
